Expert Interview
A look at gene therapies in Sickle Cell disease including Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel).
Ticker(s): VRTX, BLUE, CRSPInstitution: Cook Children's Physician Network
- Pediatric Hematologist and Director the Bleeding Disorder Program and Hemophilia Treatment Center at Cook Children's
- Manages 25 patients with Hemophilia B and 200 patients with SCD
- Clinical interest in hemoglobinopathy including sickle cell disease, thalassemia and refractoy iron deficiency anemia; Research interest in sickle cell disease and cancer (febrile neutropenia), and iron deficiency anemia.
Roughly how many patients do you treat with SCD?
Added By: sara_adminWhat percentage of your patients are eligible to receive CASGEVY or LYFGENIA?
Added By: sara_adminWhat has been your experience with reimbursement in regards to gene therapies?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
